📌 Key Takeaways
- The 26th Japanese Society of Men’s Health (JSMH) convenes
September 26–27, 2026 in Yamaguchi, Japan,
under the theme “Men’s Health Across All Life Stages.” - Three unresolved clinical questions dominate the agenda:
LOH diagnostic thresholds, TRT safety data,
and the boundary between medical treatment and wellness optimization. - The 14th Certified Testosterone Therapy Physician Examination
will be held on-site September 27 —
a credential system designed to anchor clinical standards
in a market where social media narratives often outpace evidence. - NERO will publish a post-congress follow-up
covering new evidence and any guideline developments.
“Is his testosterone low — or is this just aging?”
“Should he supplement — or not?”
In direct-pay clinics and on social media,
terms like “male menopause” and “TRT” (testosterone replacement therapy)
circulate far ahead of the clinical evidence that should govern them.
On September 26–27, 2026, the 26th Japanese Society of Men’s Health (JSMH)
convenes at KDDI Ishin Hall in Yamaguchi, Japan.
The congress theme: “Men’s Health Across All Life Stages.”
Co-hosted alongside the 17th Testosterone Research Society meeting,
the event also includes the 14th Certified Testosterone Therapy Physician Workshop and Examination.
What decisions will be made, and whether guidelines will shift,
remains to be seen.
But the reasons this congress matters are worth mapping out before it opens.
NERO is covering this in two parts: a pre-congress issue briefing (this article)
and a post-congress report on what emerged.
LOH, Andropause, TRT — When the Market Moves Faster Than the Evidence
Late-Onset Hypogonadism (LOH) — the clinical term for age-related testosterone decline
accompanied by symptomatic changes — was formally codified in Japan in 2007,
when the Japanese Urological Association and the Japan Aging Male Research Society
(now JSMH) published the LOH Syndrome Clinical Practice Guidelines,
drawing on international recommendations.
The concept is well-established.
The clinical application, however, remains contested on several fronts.
The lower limit of “normal” testosterone varies by assay method, laboratory, and guideline.
The same numerical result can be classified as “low” or “normal” depending on the reference used.
Fatigue, low motivation, and reduced libido are listed as LOH symptoms —
but they overlap substantially with depression, sleep disorders, and hypothyroidism.
“Low testosterone” is not always the correct diagnosis.
Research into TRT’s long-term cardiovascular and prostate effects is ongoing.
Neither a definitive “safe” nor a definitive “dangerous” verdict has been reached.
The evidence base is still being built.
JSMH has functioned as the primary forum for evidence-based debate
in a field where commercial messaging frequently outpaces clinical rigor.
The Certified Testosterone Therapy Physician credential system
is one institutional response to that gap.
Three Questions NERO Is Watching at This Congress
The theme — “Men’s Health Across All Life Stages” — signals a scope
broader than testosterone replacement alone.
Below are three analytical threads NERO’s editorial team is tracking.
(These reflect NERO’s editorial reading, not the official congress program.)
Debates over testosterone cutoff values, assay standardization,
and the relationship between symptom scores (e.g., AMS scale) and lab values
continue internationally.
The key question: has the field moved from simple numerical thresholds
toward a more nuanced model — identifying which symptoms,
in which patients, at which testosterone levels,
actually respond to supplementation?
TRT for anti-aging or performance optimization falls outside Japan’s public insurance system
and is offered as direct-pay care.
As aesthetic clinics and concierge practices expand TRT offerings,
how the congress frames the boundary between
“medically indicated treatment” and “performance enhancement”
will have real-world implications for clinic operators and patients alike.
The theme implies a lifespan framework spanning men in their 20s through their 80s and beyond.
Integrating frailty and sarcopenia in older men,
fertility and sexual dysfunction in younger men,
and cardiovascular risk in midlife into a coherent clinical model
is an ambitious agenda — and one that may define the society’s direction
for the next several years.
(This is NERO’s editorial analysis, not a direct reading of the official program.)
What Is a “Certified Testosterone Therapy Physician” — and Why Does It Matter?
The 14th Certified Testosterone Therapy Physician Workshop and Examination
takes place on-site on September 27.
According to JSMH, the credential certifies that a physician
“can correctly and appropriately administer testosterone replacement therapy
for hypogonadism.”
Eligibility requires being a licensed physician or dentist,
JSMH membership, completion of the workshop, and passing the examination.
Recertification is required every two years.
A searchable directory of certified physicians is maintained on the JSMH website.
Whether a physician holds the Certified Testosterone Therapy Physician credential
is one reference point worth checking when considering TRT.
The credential does not guarantee clinical excellence in absolute terms —
it indicates that the physician has completed a defined course of academic training
and passed a standardized examination.
In Japan, insurance coverage versus direct-pay status varies
by drug, indication, and clinical purpose —
so coverage eligibility must be confirmed individually.
In any consultation, it is reasonable to ask:
“For what specific purpose, with which formulation, at what dose?”
A physician who can answer that question clearly
is a meaningful signal of clinical competence.
The claim that “raising testosterone makes you feel better”
has spread widely across social media and direct-pay clinics.
But how often is the question actually being answered:
for whom, for what purpose, at what dose?
This congress exists to bring academic precision
to a field that is too often discussed in slogans.
For clinic operators running men’s health or TRT programs:
the evidence base and guideline trajectory coming out of this congress
are not optional reading — they are the clinical ground
your practice stands on.
Whether your physicians hold the Certified Testosterone Therapy Physician credential
is increasingly a factor patients will ask about.
(This is NERO’s editorial perspective, not an official statement.)
This article is Part 1 — a pre-congress issue briefing.
After September 27, NERO will publish a follow-up report covering
what was presented, whether new evidence emerged,
and whether any guideline movement was signaled.
On-demand session content (available October 27 – November 27)
will also be reviewed.
- The 26th JSMH congress (Sept 26–27, 2026, Yamaguchi)
addresses men’s health across the full lifespan —
not testosterone alone. - Three core clinical tensions remain unresolved:
LOH diagnostic thresholds, TRT long-term safety,
and the medical vs. wellness boundary. - The Certified Testosterone Therapy Physician credential
is a meaningful — though not absolute — quality signal
for patients evaluating TRT providers. - NERO will publish a post-congress report
after September 27, 2026.
accompanied by clinical symptoms — fatigue, reduced libido, mood changes.
“Low testosterone” is a lab finding; LOH is a clinical diagnosis
that requires both a qualifying lab value and symptomatic presentation.
The two are related but not interchangeable.
However, TRT administered for anti-aging, performance optimization,
or general wellness purposes is classified as direct-pay (out-of-pocket) care.
Coverage status depends on the specific drug, indication, and clinical context —
and must be confirmed with the treating physician.
certifying that a physician has completed a structured training program
and passed a standardized examination in testosterone replacement therapy.
Recertification is required every two years.
A searchable directory of certified physicians is available on the JSMH website.
Sources:
1. 26th Japanese Society of Men’s Health — Congress Overview. c-linkage.co.jp/menshealth26 (directly verified)
2. Japanese Society of Men’s Health (JSMH). Certified Testosterone Therapy Physician Workshop Announcement. jsmh.jp
